3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma
7
Lymphoma, Follicular
6
Lymphoma, Non-Hodgkin
5
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, B-Cell, Marginal Zone
4
Lymphoma, Mantle-Cell
3
Recurrence
2
Advanced Malignancies
2
Unresectable or Metastatic Solid Tumors
1
Pancreatic Neoplasms
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
B-Cell Malignancies
1
Interventions
Everolimus
5
Alpelisib
4
berzosertib
3
PX-866
3
Letrozole
3
Fulvestrant
3
Cetuximab
3
Topotecan
2
NVP-BKM120
2
tipifarnib
1
sotorasib
1
serabelisib
1
ribociclib
1
pembrolizumab
1
parsaclisib
1
palbociclib
1
gedatolisib
1
duvelisib
1
ceralasertib
1
capivasertib
1
binimetinib
1
Trimetazidine
1
Paclitaxel
1
Oxaliplatin
1
Leuprolide
1
Leucovorin
1
Irinotecan
1
Goserelin
1
Fluorouracil
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Hereditary Sensory and Autonomic Neuropathies
×
parsaclisib
×
Clear all
NCT03126019
2025-03-14
CITADEL-203
Incyte Corporation
Phase 2
Completed
126 enrolled
15 charts